CAS: 157-03-9; 6-Diazo-5-Oxo-L-Nor-Leucine

相似化合物

1118-90-7 7620-28-2 542-32-5

上下游产品

CAS号7589-24-4 6-Diazo-5-oxo-N... | CAS号56-86-0 L-谷氨酸 | CAS号25830-77-7 N-邻苯二甲酰-L-谷氨酸酐 | CAS号1676-73-9 L-谷氨酸-γ-苄酯 | CAS号84369-01-7 γ-OBzl-N-Tfa-L-... | CAS号84344-29-6 N-Tfa-L-Glu-OMe... | CAS号1535-57-5 L-n-三氟乙酰基谷氨酸酐 | CAS号71989-18-9 Fm°C-O-叔丁基-L-谷氨酸

N-Tfa-L-Glu-Ome-γ-Dcha Salt置于sodium Hydroxide,草酰氯体系中,用 甲醇 用作溶剂,化学反应 1.0H,反应生成6-重氮-5-氧代-L-正亮氨酸
参考文献:Synthesis Of The Streptomyces Ambofaciens Antineoplastic Constituent 6-Diazo-5-Oxo-L-Norleucine
标题:Synthesis Of The Streptomyces Ambofaciens Antineoplastic Constituent 6-Diazo-5-Oxo-L-Norleucine
摘要:
Doi:10.1021/jo00153A026

专利信息

专利号:US-7504231-B2
优先权日:2001-09-13
标题:Method of alleviating chronic pain via peripheral inhibition of neurotransmitter synthesis
发明人：MILLER KENNETH E
权利人:UNIV OKLAHOMA
摘要:A composition having sustained pain-relieving properties such that the composition may be administered to a subject to alleviate chronic pain. The composition includes an effective amount of at least one inhibitor of neurotransmitter synthesis. A method for alleviating chronic pain in a subject for an extended period of time is also disclosed, in which the compound is administered to a subject suffering from chronic pain at a site of inflammation such that the administration of the compound results in a reduction in at least one of thermal and mechanical pain responses at the site of inflammation for a period of at least two days without any resulting acute pain behavior. The composition may further include an effective amount of at least one compound having analgesic effects such that the composition also alleviates acute pain.

专利号:WO-0010389-A1
优先权日:1998-08-18
标题 :BLOCKADE OF GLUCOSE TOXICITY TO THE β CELLS IN THE ISLETS OF LANGERHANS
发明人：KUDLOW JEFFREY E
权利人:UAB RESEARCH FOUNDATION
摘要:The present invention demonstrates that streptozotocin (STZ) is a specific toxin for the pancreatic β cells and that STZ specifically inhibits the activity of O-GlcNAc-selective N-acetyl-β-D-glucosaminidase (O-GlcNAcase), therefore, blocks O-linked N-acetylglucosamine (O-GlcNAc) removal from intracellular proteins. The present invention is also directed to a transgenic animal with impaired glucosamine synthesis and various methods of treating diabetes and of screening for drugs for treating diabetes.

专利号:US-2007243581-A1
优先权日:2004-04-21
标题:Process for Producing Dipeptides
发明人：HASHIMOTO SHIN-ICHI; TABATA KAZUHIKO; NOGUCHI AYAKO; ADACHI YUGO
权利人:HASHIMOTO SHIN-ICHI; TABATA KAZUHIKO; NOGUCHI AYAKO; ADACHI YUGO
摘要:The present invention provides: a protein having dipeptide-synthesizing activity or a protein for dipeptide synthesis; DNA encoding the protein having dipeptide-synthesizing activity or the protein for dipeptide synthesis; a recombinant DNA comprising the DNA; a transformant carrying the recombinant DNA; a process for producing the protein having dipeptide-synthesizing activity; an enzymatic process for producing a dipeptide using the protein having dipeptide-synthesizing activity or the protein for dipeptide synthesis; and a process for producing a dipeptide using, as an enzyme source, a culture of a microorganism or a transformant having the ability to produce the protein having dipeptide-synthesizing activity or the protein for dipeptide synthesis, or the like.

专利号:US-2004126368-A1
优先权日:2001-09-13
标 题 :Method of alleviating chronic pain via peripheral inhibition of neurotransmitter synthesis

专利号:US-10568868-B2
优先权日:2015-07-31
标 题 :Methods and compositions for treating metabolic reprogramming disorders
发明人：SLUSHER BARBARA; POWELL JONATHAN
权利人:UNIV JOHNS HOPKINS
摘要:The disclosure provides methods of treating a condition, disease, or disorder in a subject that involves metabolically reprogrammed cells whose activation, function, growth, proliferation, or survival depends on increased activity of at least one metabolic pathway selected from the group consisting of glutamine metabolism, glycolysis, and fatty acid synthesis, comprising administering to the subject a compound having formula (I): n nand the pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 2 ′, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON).